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The reverse transcriptase telomerase, best known for its 
telomere maintaining function in the nucleus, exerts 
various non-canonical functions in different cellular 
locations. One of them is the shuttling of the protein 
part TERT to mitochondria where it has been shown to 
protect cells from oxidative stress, and reduce mito-
chondrial DNA damage and apoptosis [1-3]. Telomerase 
activity is high in the embryonic brain but 
downregulated early during human brain development 
and postnatally in mice [4-7]. However, the telomerase 
protein TERT has been shown to persist in adult 
mammalian brains [6, 7-11]. We recently demonstrated 
that in human hippocampal neurons from late stage 
Alzheimer’s disease (Braak stage 6) a higher amount of 
TERT protein accumulates within mitochondria 
compared  to   those  from  age-matched  healthy  brains  
 
(Braak stage 0) [10]. We also found that cultivated 
primary neurons lacking TERT were more sensitive to 
oxidative stress and to the expression of mutated hyper-
phosphorylated tau protein and displayed higher 
oxidative stress and more cellular damage compared to 
neurons from wild type, telomerase positive mice [10].  
 
Oxidative stress and mitochondrial dysfunction are well 
known to increase during aging [12-14] including brain 
aging [15, 16] and are considered a major cause for 
cellular senescence [17-19]. During aging, neurons are 
exposed to high oxidative stress and accumulate 
dysfunctional mitochondria, damage to DNA, proteins 
and lipids and changes in energy homeostasis [16, 20]. 
Recently it became evident that DNA damage during 
ageing induces a senescent phenotype even in post 
mitotic cells such as neurons [21]. These changes are 
associated with significant decrease in neuronal 


















Telomerase  in  its canonical function maintains telomeres  in dividing cells. In addition, the telomerase protein
TERT has non‐telomeric  functions such as shuttling  to mitochondria  resulting  in a decreased oxidative stress,
DNA damage and apoptosis. TERT protein persists in adult neurons and can co‐localise to mitochondria under
various  stress  conditions. We  show here  that TERT expression decreased  in mouse brain during aging while
release of  reactive oxygen  species  (ROS)  from  the mitochondrial electron  transport  chain  increased. Dietary
restriction (DR) caused accumulation of TERT protein in mouse brain mitochondria correlating to decreased ROS
release and improved learning and spatial short‐term memory. Decreased mTOR signalling is a mediator of DR.
Accordingly,  feeding  mice  with  rapamycin  increased  brain  mitochondrial  TERT  and  reduced  ROS  release.
Importantly,  the  beneficial  effects  of  rapamycin  on  mitochondrial  function  were  absent  in  brains  and
fibroblasts  from  first  generation  TERT  ‐/‐  mice,  and  when  TERT  shuttling  was  inhibited  by  the  Src  kinase
inhibitor  bosutinib.  Taken  together,  our  data  suggests  that  the  mTOR  signalling  pathway  impinges  on  the
mitochondrial localisation of TERT protein, which might in turn contribute to the protection of the brain by DR
or rapamycin against age‐associated mitochondrial ROS increase and cognitive decline.  
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functions such as learning and memory even without 
obvious pathology in older people. They are further 
exacerbated in neurodegenerative diseases such as 
Alzheimer’s (AD), Parkinson’s (PD), after stroke and 
brain injury [22- 25].  
 
Dietary restriction (DR) is a non-genetic intervention 
that reproducibly increases mean and maximum lifespan 
and delays the onset of age-related pathologies in a 
wide range of tissues including in the brain. The 
influence of DR on brain aging, neuroplasticity, 
neuroprotection and cognitive performance has been 
evaluated in rodent models [26-28]. DR has been shown 
to improve cognition and spatial memory [29], motor 
and learning tasks in rodents [30] and slow down the 
progression of neurodegenerative diseases, such as 
Alzheimer’s disease (AD) [31, 32]. Beneficial effects of 
DR on mitochondrial function in different tissues have 
been well documented [see 33 for review] and we have 
recently shown that DR decreased mitochondrial 
reactive oxygen species (ROS) production and 
prevented age-dependent deterioration in mitochondrial 
coupling by improving the assembly of the electron 
transport chain complex I in mouse liver and brain [14].  
 
The underlying molecular mechanisms responsible for 
the beneficial effects of DR are thought to be 
multifactorial: changes in metabolic signalling via the 
insulin/IGF axis, sirtuin, AMPK and mTOR pathways 
have been suggested as mechanisms associated with 
improved health and longevity after DR [34, 35] and 
these pathways are also implicated in the aging process 
[36, 37]. mTOR is a highly conserved serine/threonine 
protein kinase complex which responds to the levels of 
nutrients and cellular energy conditions responsible for 
cell growth, size, metabolism and survival. This 
pathway is activated by the amount of nutrients in a cell 
and down-regulated during DR and rapamycin treat-
ment. Rapamycin feeding in mice also extended 
lifespan [38, 39] and reduced mitochondrial ROS 
production [14, 18]. However, the effects of rapamycin 
treatment are not identical to that of DR [39, 40]. 
 
The aim of this study was to explore whether 
mitochondrial TERT protein is protective for the brain 
in vivo and whether it plays a role in the beneficial 
effects of DR and after rapamycin treatment on 
mitochondrial and brain functions.  
 
Our results demonstrate that DR and the decrease of 
mTOR activity by rapamycin treatment might be novel 
and physiologically relevant stimuli to promote 
mitochondrial TERT localisation specifically in brain in 
vivo resulting in improved mitochondrial function. 
Importantly, the reduction in mitochondrial ROS release 
by rapamycin treatment was absent in first generation 
TERT -/- mice, suggesting that TERT was required for 
the effect. These results are supported by mechanistic 
data in vitro showing that the decrease of ROS after 
rapamycin treatment depends on the presence of TERT 
as well as Src kinase dependent exclusion of TERT 
from the nucleus. Our data suggest that an increase in 
mitochondrially localised TERT protein might 
contribute causally to the beneficial effects of DR and 




Mitochondrial ROS release increases during aging in 
brain and is rescued by DR 
 
We performed a long term DR experiment on C57BL6 
mice and studied mitochondrial function in brains 
during aging and the influence of DR. Release of 
hydrogen peroxide (H2O2) from complex I of the 
electron transport chain in isolated brain mitochondria 
increased with age, determined as its maximum capacity 
in the presence of the complex I-linked substrate 
pyruvate plus malate and the complex I inhibitor 
rotenone (Fig. 1A). There was also an age-dependent 
increase in the rate of H2O2 release from mitochondria 
when they were supplemented with the complex II-
linked substrate, succinate (Fig. 1B). DR completely 
rescued the increase in both parameters until at least 15 
months of age and still showed a partial rescue at 24 
months, indicating that DR postponed the age-
dependent increase in H2O2 release from brain 
mitochondria.  
 
DR improves learning and spatial memory in old 
mice  
 
In order to correlate the changes in mitochondrial 
function during aging and in DR with brain function we 
performed a Barnes maze test for spatial learning and 
memory on young (10 months) and old AL mice (30 
months) as well as old mice on long term DR (33 
months). This test included a learning period of 4 days 
with a test of short term spatial memory on day 5 and 
long term memory on day 12.  
 
Fig. 2A demonstrates that old AL and DR mice were 
significantly slower than young mice in finding the 
target hole at the start of the experiment (day 1) 
presumably due to increased anxiety in the old mice. 
However, from the 3rd day of training it became clear 
that DR mice learned much better than AL mice, 
becoming indistinguishable from the young group and 
significantly different from the AL mice at the end of 
the training period. In addition, short term memory, 
measured as the time to locate the target hole on day 5, 
was superior in DR mice compared to AL mice and 
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reached a similar level as that in young mice (P<0.05) 
(Fig. 2B, left bars). In contrast, there were no 
differences in long term memory measured  as  the  time 
to find the target hole although the groups showed 
similar tendencies (Fig. 2B, right bars). Equally, hole 
scores, another measure for spatial memory, showed 
corresponding tendencies for a decrease with age and an 
improvement during DR for both short- and long term 
memory, but did not reach statistical significance (Fig. 
2C).  
 
TERT protein levels in whole mouse brain decrease 
with age but DR enhances brain mitochondrial 
TERT abundance 
 
We analysed TERT expression in brains from 4 and 21 
months old mice using qPCR and found a significant 
decrease of TERT mRNA at old age (P<0.05, t- test), 
(Fig. 3A). TERT protein abundance also decreased with 
age in homogenates from 2 different brain regions 
(cortex and cerebellum) (Fig. 3B). In agreement with 
earlier data [6] there was no telomerase activity in brain 
homogenates from old mice (data not shown). In order 
to examine whether DR affects TERT abundance and 
intracellular localisation, we measured TERT 
abundance in brain homogenates and in matching 
mitochondrial fractions in 3 independent short term DR 
experiments (see Table 1 for details) (Fig. 3 C-E). In all 
3 experiments which varied by age of onset and 
duration of DR we found a significant increase of TERT  

























after DR while there was only in one experiment 
(number 2, see Table 1) an increase in the whole brain 
homogenate (Fig. 3 C-E). This increase of 
mitochondrial TERT under DR was tissue-specific: 
there was no consistently significant increase in TERT 
abundance in either homogenates (with the exception of 
exp 1) or isolated mitochondria from livers of the same 
mice (Suppl. Fig. S1A-C). Moreover, telomerase 
activity in liver did not increase under DR with the 
exception of exp 3 (Suppl. Fig. S1D-F).  
 
We confirmed the purity of the mitochondrial fractions 
from brain using Western blot using antibodies against 
HDAC II (histone deacetylase II, nuclear fraction) and 
Cox II (cytochrome c oxidase II, mitochondrial fraction, 
and beta-tubulin for the cytoplasmic fraction (Suppl. 
Fig. S2). Mitochondrial fractions showed only Cox II 
signals, while nuclear and cytoplasmic proteins were 
only detected in the homogenates.  
 
Together, we demonstrate that TERT protein 
accumulates specifically in brain mitochondria after 
DR, but not in liver tissue. 
 
Rapamycin increases mitochondrial TERT 
abundance in brain and decreases mitochondrial 
ROS release from wild-type but not TERT-/- mice  
 
It has been thought that many, but not all, effects of DR 
are mediated by suppression of mTOR signalling [35]. 

























Figure  1. DR  delays  age‐related  increase  in  hydrogen  peroxide  release  from mouse  brain mitochondria.    (A)
Hydrogen peroxide release from  isolated mouse brain mitochondria measured using the Amplex red method at 3, 15 and 24
months under AL  and DR  conditions: Complex  I  linked  substrate, pyruvate/malate  (PM, 5mM)  in  the presence of  rotenone
(5µM) (maximum capacity). (B) Complex II linked substrate, succinate (4mM). Between 4 (3 months) and 9 (15 months AL) mice
per  group were  used.  Data  are mean  ±  S.E.M.  Significance  for  age‐related  increase was  analysed  using  One way  ANOVA
compared to 3 months old brains. Differences between AL and DR at each age were compared by t‐test. *P<0.05, ***P<0.001. 
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sible for DR-induced mitochondrial TERT 
accumulation and ROS reduction, mice were treated 
for 4 months with the mTOR inhibitor rapamycin. We 
confirmed suppression of mTOR signalling in brain 
under short-term DR by showing reduced 
phosphorylation of mTOR and its downstream target 
ribosomal protein S6 (experiment 2 in Table 1, Suppl. 
Fig. S3A, B). 4 months rapamycin treatment did not 
change the body weight of mice (Suppl. Fig. S3C). As 
expected, there was significantly less mTORC1 
phosphorylation in brains after rapamycin feeding than 
in controls (Suppl. Fig. S3D). In addition, rapamycin 
treatment increased TERT transcription in the brain 
(Suppl. Fig. S3E). Importantly, TERT protein 
abundance under rapamycin was increased specifically 
in brain mitochondria but not in tissue homogenate 
(Fig. 4A). 
 
To test if a higher abundance of mitochondrial TERT 
causally contributed to a decrease in mitochondrial ROS 
release via reduced mTOR signalling, we used TERT-/- 



































the rates of mitochondrial H2O2 release with that of wild 
type mice. Mitochondrial H2O2 release was decreased in 
brains from rapamycin-treated wild type mice with both 
complex I and II linked substrates  (Fig. 4B, C) but 
critically, not in TERT -/- mice (Fig. 4B, C). This data 
suggests that the decrease in mitochondrial ROS release 
after rapamycin treatment depends on the presence of 
TERT. 
 
Rapamycin treatment induces Src dependent 
shuttling of TERT out of the nucleus causing ROS 
decrease  
 
To examine the effects of rapamycin on TERT shuttling 
from nucleus to mitochondria in vitro, we first treated 
TERT-positive MCF-7 human breast cancer cells with 
rapamycin for 3 days. We found a dose-dependent 
exclusion of TERT protein from the nucleus by 
rapamycin (Fig. 5A). Since TERT nuclear exclusion 
had been shown previously to be dependent on Src 
kinase [41] we applied the Src inhibitor bosutinib 













































































Indeed, rapamycin-driven shuttling of TERT was 
entirely dependent on the presence of functional Src 
kinase (Fig. 5A, red bars). Shuttling of TERT from 
nucleus to mitochondria reduced mitochondrial ROS 
production in multiple cell types [1, 2, 42]. 
Accordingly, a concentration-dependent decrease of 
intracellular ROS levels was found in rapamycin-treated 
MCF-7 cells which became significant at 200nM 
rapamycin (Fig. 5B). The reduction of ROS by 
rapamycin was completely diminished by the Src kinase 
inhibitor bosutinib (Fig. 5B).  
 
In order to test the dependency of a ROS decrease on 
the presence of TERT as shown in brain mitochondria 
after rapamycin treatment in vivo (Fig. 4B, C) we 
employed mouse ear fibroblasts obtained from either 
wild type mice or first generation TERT knock-out mice 
and treated these cells with rapamycin for 3 days (Fig. 
5C). We found the same rapamycin concentration-





































fibroblasts as in MCF7 cells. Moreover, inhibition of 
TERT shuttling by bosutinib again blocked the 
reduction of ROS by rapamycin. Importantly, 
rapamycin did not cause a decrease of ROS in 
fibroblasts lacking the TERT protein. Together, these 
results suggest that the beneficial effect of rapamycin on 
the decrease of ROS in TERT-positive cells depends at 
least partially on the capability of rapamycin to induce 
nuclear export of TERT protein into mitochondria, where 




Mitochondrial dysfunction and increased oxidative 
stress are associated with cellular senescence [17, 18] as 
well as aging [14]. We and others had previously shown 
that the telomerase protein TERT is able to improve 
mitochondrial function and to decrease oxidative stress 
[1-3]. In addition, it was demonstrated that although 
telomerase activity is downregulated early during 
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human brain development [5, 7] and soon after 
postnatal development in mouse brains [6], TERT 
protein persists in adult mammalian brain and can enter 
neuronal mitochondria in vivo [10]. So far, oxidative 
stress, radiation or treatment with chemotherapeutic 
drugs such as etoposide have been shown to function as 
triggers for mitochondrial localisation of TERT in 
cellular models [1-3]. Recently Eitan et al. [9] showed 
that also glutamate stress in vivo can increase mito-
chondrial TERT in Purkinje neurons.  
 
It is well established that suppression of mTOR 
signaling can postpone aging and increase lifespan in 
multiple organisms [35, 39]. It is also known that 
mTOR is expressed in the developing and adult brain 
where it is involved various functions, such as synaptic 
plasticity, adult neurogenesis, memory, and learning 
[43- 45]. Haloran and colleagues showed that rapa-
mycin treatment in mice improved brain function such 
as learning and memory in a Morris water maze [45]. 



































cin treatment had beneficial effects on brain function 
and prevented cognitive decline of a mouse model of 
Alzheimer’s disease [46]. We and others have 
demonstrated that rapamycin treatment can delay 
cellular senescence by improving mitochondrial 
properties by suppressing mitochondrial biogenesis and 
increasing retrograde signalling from mitochondria [18, 
47].  
 
Here, we show for the first time that DR and reduced 
mTOR signalling are physiologically relevant novel 
stimulators for mitochondrial TERT accumulation in 
brain in vivo, and TERT is causally involved in the 
effects of rapamycin on reduced mitochondrial ROS 
release. This result is in agreement with previous data of 
an inverse correlation between mitochondrial TERT 
localisation and mitochondrial ROS levels in different 
cell types in vitro including cultivated neurons [1-3, 10]. 
Cognitive function declines during aging [48]. This 
results in changes of learning and memory, which have 




































Mouse  TERT protein  abundance  in brain homogenates  and  isolated mitochondria  after 4 months  rapamycin  treatment.  (n=5 per
group, t‐test, ***p<0.001). (B) H2O2 release (as percentage of controls) from brain mitochondrial complex I (maximum capacity, with
complex I‐linked substrate, pyruvate plus malate in the presence of rotenone ) from wild‐type (WT) or first generation TERT‐/‐ mice
fed  either  control  or  rapamycin‐containing  diet  for  4  months.  (n=4‐5  per  group,  t‐test:  *P<0.05)  (C)  H2O2  release  from  brain
mitochondria as measured in (B), but with the complex II‐linked substrate, succinate (4mM). n=4‐5 mice per group, t‐test *P<0.05.  
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with these findings we demonstrate in this study that 
long term DR for 30 months improves spatial learning 
and short term spatial memory to a level 
indistinguishable from the younger mice while old AL 
mice at the same age as the DR mice were impaired in 
their learning ability. Although correlative, our results 
suggest that the changes in brain function might be 
associated to mitochondrial function and ROS release 
from the organelles.  
 
Using a TERT-/- mouse model, we provide evidence 
that rapamycin mediated reduction in mitochondrial 
ROS release in brain tissue depends on the presence of 
TERT since we did not see a decreased ROS release in 
TERT-/- mice. First generation TERT knockout mice 
used here have similarly long telomeres as wild type 
mice [51], excluding telomere length-dependent effects 
as a cause of these differences.  
 
Several factors can influence changes in mitochondrial 




































rial ROS release by DR in brain may thus be at least 
partly explained by its effects on reduced mTOR 
signalling which promotes TERT protein to localise to 
mitochondria. There are a number of well-documented 
mechanisms by which the mTOR pathway is involved 
in mitochondrial homeostasis, such as regulation of 
mitophagy and protein synthesis [52]. Our data suggest 
an additional mechanism by which reduced mTOR 
signalling might improve mitochondrial quality and 
function, namely by directing TERT protein into the 
organelle. Several studies have shown that mito-
chondrial TERT has various functions within the 
organelle [1-3, 42]. These include decrease of mito-
chondrial superoxide and intracellular peroxides [1, 2], 
decreased apoptosis and less damage to mitochondrial 
DNA [1] and nuclear DNA [3], improved respiration 
and binding to mitochondrial genes [2, 42] and 
functioning as a reverse transcriptase within mito-
chondria by using various mitochondrial RNAs as 
templates [42]. Thus, the telomerase protein TERT 


































Figure  5.  Rapamycin  causes  nuclear  exclusion  of  TERT  and  reduces  cellular  ROS  levels  in  a  TERT‐dependent
fashion.  (A) Extranuclear TERT  levels  (as  fraction of  total cellular anti‐TERT  immunofluorescence signal)  in MCF7 cells  treated
with the indicated concentrations of rapamycin. Bosutinib (1µM, red bars) was added to inhibit Src kinase. (*P<0.05, ANOVA for
rapamycin concentration dependency and t‐test for the effect of bosutinib at each rapamycin concentration) (B) Intracellular ROS
levels  (average DHR  fluorescence  intensity  in  flow cytometry, as percentage of untreated controls)  in MCF‐7 cells  treated with
rapamycin  (concentrations  indicated).  B  denotes  additional  treatment  with  1  μM  bosutinib.  (*  p<0.05,  ANOVA,  n=3‐4  per
condition)  (C)  Intracellular ROS  levels  in primary mouse ear  fibroblasts  from wild  type  (WT,  left columns) and  first generation
TERT‐/‐  (right  columns) mice  treated as  in 5B.  (2 way ANOVA, * p<0.05,  for  influence of  rapamycin and  genotype, n=7‐8 per
condition). Bosutinib treatment (middle column group) and lack of TERT (right columns) prevent decrease of ROS after rapamycin
treatment in primary mouse ear fibroblasts, * p<0.05, One way ANOVA and Dunn’s post hoc test, n=7‐8 per condition. 
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that might improve mitochondrial function and decrease 
ROS release under DR or conditions of reduced mTOR 
signalling. 
 
Furthermore, the effect of DR on changes in 
mitochondrial TERT abundance was absent in liver, 
suggesting there may be important roles of TERT 
specifically in brain as shown by Iannilli and colleagues 
through the existence of cytoplasmic TERT in a 
complex with RNA granules binding p15INK4B RNA 
and regulating it’s translation in mature neurons 
providing another pro-survival function in these cells 
[53].  
 
Modelling the decrease in ROS following rapamycin 
treatment in vitro we found that presence of TERT and 
its nuclear exclusion are both required for the reduction 
of ROS production by rapamycin. Using either TERT 
knock-out cells or blocking TERT nuclear exclusion 
with the Src inhibitor bosutinib abrogated the decrease 
of intracellular peroxides after rapamycin treatment. 
Together, our data suggest that the mTOR pathway 
might have a pleiotropic effect on the subcellular 
shuttling of TERT to mitochondria. The nuclear 
exclusion of TERT in our cellular model was 
quantitatively less pronounced than that caused by 
chronic, high oxygen partial pressure or acute hydrogen 
peroxide treatment [1, 3]. This might be due to a slow 
kinetics of TERT shuttling driven by mTOR suppression 
similar to the one observed under hyperoxia [1].  
 
In addition, we demonstrate here that TERT levels 
decrease in brain tissue with age in mice at both mRNA 
and protein levels. In contrast, both DR and rapamycin 
feeding increased mitochondrial TERT but had no 
effects on TERT abundance in whole brain 
homogenates. It had been shown previously that various 
stimuli that mimic aspects of DR, such as resveratrol 
and exercise, can increase cellular telomerase activity 
and TERT expression in different human cell types such 
as endothelial progenitor cells in vitro and PBMCs in 
vivo [54, 55] and might thus have beneficial anti-aging 
effects. However, the DR mimetic rapamycin has been 
reported to decrease telomerase activity and TERT 
protein levels in cancer cells in the absence of 
transcriptional changes in TERT expression [56]. This 
could mean that the regulation of TERT expression after 
rapamycin treatment might be different in brain tissue in 
vivo where we found an increased TERT expression 
after rapamycin treatment in mice than in cancer cells in 
vitro. Several groups reported that TERT can form a 
complex with mTOR and other proteins such as 
PI3K/Akt, Hsp90 and S6 kinase in cancer cells [56, 57]. 
This complex might be involved in the upregulation of 
telomerase/TERT during transcription as well as post-
transcriptionally during IL-2 activation of transformed 
immune cells [57, 58]. Interestingly, Sundin et al. [56] 
reported that rapamycin is able to disrupt this 
mTor/TERT/Hsp90/S6K complex post-translationally. 
However, it is not known whether similar complexes 
form also in other cell types and in tissues in vivo and if 
they do, whether they impact on the subcellular 
localisation of TERT.  
 
Taken all our results together, we suggest that TERT 
protein might be a mediator of the beneficial effects of 
DR by improving mitochondrial function in brain 
through reduced mTOR signalling. 
 
MATERIALS AND METHODS 
 
Cells and treatments 
 
MCF-7 cells (ATCC), were cultivated as described in 
[3]. Primary mouse ear fibroblast were isolated and 
cultivated as follows:  
 
Mouse ear notches or whole ears were collected and 
stored in cold Serum Free Medium (SFM), Advanced 
DMEM/F12 (Life Technologies) chopped with a sterile 
scalpel and incubated in SFM with 1mg/mL of 
collagenase A (Roche) for 1.5h at 37°C in 5% O2. After 
digestion, the tissue was passed through an 18G syringe 
needle and then centrifuged for 10 minutes at 1000 rpm. 
Next, pellets were resuspended in advanced DMEM/F12 
medium with 10% FBS (SIGMA), 2mM L-glutamine 
(GIBCO) and a mix of 50U/mL penicillin and 10mg/mL 
streptomycin (GIBCO). Isolated cells were incubated and 
cultivated at 37°C in 3% O2 and 5% CO2.  
 
Cells were treated with 100 or 200nM rapamycin 
(SIGMA) in serum containing medium for 3 days. 
Controls were treated with the same amount of DMSO. 
Bosutinib (Santa Cruz Biotechnology) was also prepared 
in DMSO and controls treated with DMSO only. 
 
Mice and treatments 
 
In the late onset dietary restriction study (experiment 1), 
the mouse strain ICRFa on a C57BL/6 background was 
used [59]. Mice used in DR experiments 2 - 4 were the 
inbred C57BL/6 strain from Harlan, (Blackthorn, UK). 
mTert-/- mice (strain:B6.129S-Tert, tm1Yjc/J, [60] were 
purchased form the Jackson Laboratory (USA) and 
were bred to obtain wild type, first generation (F1) 
knockout and heterozygote mice. Mice used in all 
experiments were group-housed in the same room and 
were provided with sawdust as well as paper bedding. 
Mice were accommodated at 20 ± 2 °C under a 12 h 
light/12 h dark photoperiod with lights on at 7 am. All 
animals had ad libitum access to water. AL (ad libitum) 
fed mice had 24h access to standard rodent pelleted 
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chow while the DR (dietary restricted) mice received a 
smaller pellet size (4 mm), both from Special Diets 
Services, Witham, UK. The reduction in food intake for 
the DR experiments was calculated from the food intake 
of the control AL group in each experiment [61]. Onset 















For rapamycin treatment 12 months old TERT-/- and 
wild type littermates received encapsulated rapamycin 
supplementation [38] for 4 months, thus mice were 16 
months old when used. The dose of rapamycin was 14.7 
mg per kg mouse as described in [38]. The experimental 
chow was a gift from Randy Strong (The University of 
Texas Health Science Centre) while controls received 
the same food without rapamycin encapsulation. 
 
The project was approved by the Faculty of Medical 
Sciences Ethical Review Committee, Newcastle 
University. Experiments were conducted in accordance 
with UK Home Office legislation under the Animals 
(Scientific Procedures) Act 1986. The work was 
licenced by the UK Home Office (PPL 60/3864) and 
complied with the guiding principles for the care and 




Frozen mouse brains were ground with a customised 
tissue grinder in  liquid  nitrogen  and  stored  at  -80 °C.  
RNA was isolated from 30mg of powder using 












manufacturer’s protocol. Reverse transcription was 
performed with 1µg of RNA and SuperScript® III 
Reverse Transcriptase (Invitrogen).  
 
mTERT expression in the brain  samples  was  analysed  















as reference gene in the analysis using the 
SensiFAST™ SYBR® Hi-ROX (Bioline), on a Step 
One Plus instrument (Applied Biosystems) with the 
programme consisting of 95 °C for 2 min, 50 cycles of 5 
seconds at 95 °C and 20 seconds at annealing 
temperature of each primer pair and a melt analysis step 
at gradually increased temperature from 68 °C to 95 °C. 
The expression of mTERT was normalised to the expres-
sion of the housekeeping gene mGAPDH and the results 
were calculated and reported with the format of compara-
tive threshold cycle (ΔΔCT). Sequence and annealing 




TERT protein abundance in brain tissues and 
mitochondrial fractions was assessed using the TERT 
ELISA Assay (GenWay) including an internal standard. 
Cell pellets, homogenised or ground tissues and 
mitochondrial pellets were lysed in CHAPS buffer 
(Roche) and the ELISA performed with 100μg protein as 
described in [10]. Specificity was tested by using mouse 















Experiment Genotype Sex Food 
restriction[%] 
Age at DR 
onset (months) 




1 ICFRa males 26 15 17.3 2.3 
2 C67BL/6 males 40 3 9 6 
3 C67BL/6 males 40 3 6 3 
4 C67BL/6 males and 
females 
40 3 24 21 
5 TERT-/- males 40 6 22 16 
Table 2. Primer sequences and PCR conditions for qPCR 
 
Name  Sequence Annealing temperature 
mTERT forward 5’-GGATTGCCACTGGCTCCG 
68 °C 
mTERT reverse 5’-TGCCTGACCTCCTCTTGTGAC 
mGAPDH forward 5’-GAACGGGAAGCTCACTGGC 
62 °C 
mGAPDH reverse 5’-GACAACCTGGTCCTCAGTGT 
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Generation of mouse brain homogenate and isolation 
of mitochondria  
 
The method was performed as described [14]. In brief: 
Whole brains were placed in ice cold isolation medium 
(250 mM Sucrose, 10mM Tris, 0.5mM EDTA pH 7.4 at 
4°C) immediately after killing the mice, and transferred 
to the Dounce glass tissue grinder to homogenise. An 
aliquot of the homogenates was immediately snap 
frozen and stored at -70°C. Brain mitochondria were 
isolated from the rest of the homogenates according to 
[62].  
 
Hydrogen peroxide release from mitochondria 
 
The experiments were performed as published in [14, 
63]. In brief, H2O2 release from isolated brain 
mitochondria was measured in assay buffer containing 
115 mM KCl, 10 mM KH2PO4, 2 mM MgCl2, 3 mM 
Hepes, 1 mM EGTA, 0.2% fatty acid free BSA, pH 7.2 
at 37°C in the presence of exogenous superoxide 
dismutase (75 U/ml), horseradish peroxidase (HRP) (2 
U/ml) and Amplex Red (50µM, Thermo Fisher) at 
37°C. The fluorescent intensity of resorufin, the 
oxidised product of Amplex Red, was monitored 
kinetically in a plate reader (FLUOstar Omega, BMG 
Labtech) at the excitation and emission wavelengths of 
544 nm and 590 nm, respectively. Mitochondria were 
supplemented with either complex I (Pyruvate + malate, 
PM, 5mM) or complex II (succinate, 4mM). The 
maximum capacity of complex I to release H2O2 was 
determined in the presence of rotenone (5µM) with 
complex I linked substrate.  
 
ROS determination in cells using flow cytometry 
 
Intracellular ROS levels of MCF7 and mouse ear 
fibroblasts were determined by staining of cells with 80 
μM dihydrorhodamine 123 (DHR, Molecular Probes) 
and measuring in the green (FL1) and red (FL3) 
channels of a Flow cytometer (Partec, Muenster, 
Germany) as described in [1, 17]. 
 
Immuno-fluorescence staining for hTERT in MCF7 
cells 
 
Immuno-fluorescence staining was performed using the 
TERT antibody (Rockland, USA) as described in [1, 3]. 
In brief: cells were grown on cover slips for 3 days and 
treated with 100 and 200nM rapamycin and DMSO for 
control. Cells were fixed with 4% PFA and stained with 
TERT primary and Alexafluor554 secondary antibody. 
At least 10 cells were analysed per condition and the 
amounts of TERT within the nucleus and cytoplasm 
determined using ImageJ software. 
Behaviour test: Barnes maze for spatial learning and 
memory 
 
The Barnes Maze was used to assess spatial learning and 
memory which is predominantly determined by the 
hippocampus and is described in detail in [64]. Mice 
were allocated a specific target hole on a round disc with 
20 holes and 4 visual clues on 4 sides. We did not use 
any adverse stimuli to promote mice to find their target 
holes (TH). On four consecutive days of learning 4 trials 
per day for 3 minutes each were performed. If mice did 
not find their allocated target hole within that time a 30 
extra seconds were added to their time. For assessing and 
scoring the short and long term memory on days 5 and 
12, respectively, mice were given one trial of 90 seconds 
to find their TH, which did not offer the escape box 
beneath the table. For failed attempts to find the TH an 
additional 20 seconds were added to the 90 seconds. In 
addition to the time to allocate the TH, a hole score was 
determined as the ratio between the sum of the value of 
each hole where mice poked their head into (10 for the 
target hole and one less for each consecutive neighbour-
ing hole) and the number of total head pokes into holes.  
 
Statistical analysis 
    
For the comparison of 2 groups Student’s t-test was 
applied. To examine statistical significance of normally 
distributed data One Way ANOVA and Two Way 
ANOVA tests were performed with appropriate post-hoc 
tests using Sigmaplot® software. Non-parametric data 
sets where tested by One Way ANOVA on ranks or 
Mann-Whitney Rank sum test. All data are presented as 
mean and error bars are standard error of the mean 
(S.E.M) unless otherwise stated. Results were considered 
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fed  controls)  in  liver  homogenates  in  the  same DR  experiments  as  above.  (A, D)  Experiment  1;  4  animals  per  group.  (B,  E)
Experiment  2,  n=4  per  group.  (C,  F)  Experiment  3,  n=7  per  group  for  mitochondria  and  n=3  per  group  for  homogenates.
*Statistical significance was tested by t‐ test. * p<0.05. 

































































































Tissue homogenates and mitochondria were lysed using 
CHAPS buffer (Roche). 60µg protein per sample was 
run on 10% polyacrylamide gel and blotted to ECL 
membrane (GE Healthcare) at 100V for 90 min. at 4°C, 
blocked and incubated with the primary antibody 
diluted over night at 4°C, After washing with TBST 
buffer and incubation with a peroxidase labelled 
secondary antibody membranes were developed with t a 
chemiluminescence detection kit (GE Healthcare) 
images were taken with a LAS 3000® camera (Fujifilm) 
and quantified by densitometry and normalised to the 





Telomerase was determined using the TeloTTAGGG 
telomere repeat assay (Roche) as described previously 
[7, 10] using 100ng liver tissue per reaction and a serial 








antibody manufacturer dilution 
HDACII Abcam 1:800 
CoxII Santa Cruz 1:200 
phospho-mTOR (Ser2448) Abcam 1:500 
mTOR Abcam 1:500 
phospho-S6 Cell Signalling 1:1000 
S6 Cell Signalling 1:1000 
β-tubulin Abcam 1:1000 
